Courtney Dugan | Investor Relations |
Mitchell Gold | Chairman & Chief Executive Officer |
Stanford Peng | President & Head, Research & Development |
Paul Rickey | Chief Financial Officer |
Mark Breidenbach | Oppenheimer & Co. |
Ted Tenthoff | Piper Jaffray |
Wangzhi Li | Ladenburg |
Robert Driscoll | Wedbush Securities |
Operator | |
Good afternoon | ladies and gentlemen - and thank you for joining the Alpine Immune Sciences' Third Quarter 2019 Company Update Conference Call. All participants are in a listen-only mode. Following opening remarks - Alpine's management will open the lines for a question-and-answer period. Please be advised this call is being recorded at the company's request and a webcast of this call will be archived on the company's website for approximately two week. |
I would now like to introduce Courtney Dugan | Investor Relations. Please go ahead. |
Thank you, operator and thank you everyone for joining us on today's call. This afternoon we issued a press release announcing our corporate update and third quarter 2019 financial results, which is available on the Investor Relations section of our website.
Before we begin today's discussion, I'd like to note that during the call, we will be making certain forward-looking statements, including statements regarding our platform technology and potential therapies; the timing of, and results from, clinical trials and pre-clinical development activities; clinical and regulatory objectives; expectations regarding the sufficiency of cash to fund operations; the potential efficacy, safety profile, and commercial potential of our product candidates; the timing of our public presentations and potential publication of future clinical trial data; the efficacy of our clinical trial designs; expectations regarding our ongoing collaborations; and our ability to successfully develop and achieve milestones and our development programs.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time-to-time in our SEC filings.
Our results may differ materially from those projected on today's call.